Topic
Bovine serum albumin
About: Bovine serum albumin is a research topic. Over the lifetime, 19981 publications have been published within this topic receiving 571291 citations. The topic is also known as: BSA.
Papers published on a yearly basis
Papers
More filters
TL;DR: A simple, one-pot, "green" synthetic route, based on the "biomineralization" capability of a common commercially available protein, bovine serum albumin (BSA), has been developed for the preparation of highly stable Au nanocrystals (NCs) with red emission and high quantum yield.
Abstract: A simple, one-pot, "green" synthetic route, based on the "biomineralization" capability of a common commercially available protein, bovine serum albumin (BSA), has been developed for the preparation of highly stable Au nanocrystals (NCs) with red emission and high quantum yield.
2,215 citations
TL;DR: A sensitive method to determine the free amino groups in proteins is presented that makes use of the reagent 2,4,6-trinitrobenzenesulfonic acid and found that sodium dodecyl sulfate was bound to some of the ϵ-amino groups of lysine in bovine serum albumin, ovalbumin, and human γ-globulin and rendered the involved amino groups unreactive toward TNBS.
1,972 citations
TL;DR: The molecular weight-slope relation was established utilizing 17 well-characterized proteins as standards and it is possible to determine the molecular weight of a protein with an average precision of ±4%.
1,823 citations
TL;DR: N-terminal region sequence analysis of the molecule has identified the cofactor as beta 2-glycoprotein I (beta 2GPI) (apolipoprotein H), a plasma protein known to bind to anionic phospholipids, indicating that the presence of beta 2G PI is an absolute requirement for antibody-phospholipid interaction.
Abstract: Anti-phospholipid (aPL) antibodies that exhibit binding in cardiolipin (CL) ELISA can be purified to greater than 95% purity by sequential phospholipid affinity and ion-exchange chromatography. However, these highly purified aPL antibodies do not bind to the CL antigen when assayed by a modified CL ELISA in which the blocking agent does not contain bovine serum, nor do they bind to phospholipid affinity columns. Binding to the phospholipid antigen will only occur if normal human plasma, human serum, or bovine serum is present, suggesting that the binding of aPL antibodies to CL requires the presence of a plasma/serum cofactor. Using sequential phospholipid affinity, gel-filtration, and ion-exchange chromatography, we have purified this cofactor to homogeneity and shown that the binding of aPL antibodies to CL requires the presence of this cofactor in a dose-dependent manner. N-terminal region sequence analysis of the molecule has identified the cofactor as beta 2-glycoprotein I (beta 2GPI) (apolipoprotein H), a plasma protein known to bind to anionic phospholipids. These findings indicate that the presence of beta 2GPI is an absolute requirement for antibody-phospholipid interaction, suggesting that bound beta 2GPI forms the antigen to which aPL antibodies are directed. Recent evidence indicates that beta 2GPI exerts multiple inhibitory effects on the coagulation pathway and platelet aggregation. Interference with the function of beta 2GPI by aPL antibodies could explain the thrombotic diathesis seen in association with these antibodies.
1,598 citations
TL;DR: A relatively simple but sensitive and reliable method of quantitating the oxygen-radical absorbing capacity (ORAC) of antioxidants in serum using a few microliter is described, which solves many problems associated with kinetics or lag-time measurements.
1,528 citations